"Amsacrine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
| Descriptor ID |
D000677
|
| MeSH Number(s) |
D03.633.300.046.250.225
|
| Concept/Terms |
Amsacrine- Amsacrine
- Cain's Acridine
- Cain Acridine
- Cains Acridine
- meta-AMSA
- meta AMSA
- AMSA
- m-AMSA
Amsidine- Amsidine
- Amsacrina
- AMSA P-D
- AMSA P D
- AMSA PD
|
Below are MeSH descriptors whose meaning is more general than "Amsacrine".
Below are MeSH descriptors whose meaning is more specific than "Amsacrine".
This graph shows the total number of publications written about "Amsacrine" by people in this website by year, and whether "Amsacrine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Amsacrine" by people in Profiles.
-
Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs. Biochemistry. 1997 Mar 11; 36(10):2919-24.
-
The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995 Sep 15; 86(6):2091-7.
-
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia. 1994 Aug; 8(8):1269-74.
-
Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes. Cancer Chemother Pharmacol. 1994; 34 Suppl:S19-25.
-
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Cancer Chemother Pharmacol. 1994; 34(3):249-56.
-
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991. Leukemia. 1992; 6 Suppl 2:78-80.
-
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital. Leukemia. 1992; 6 Suppl 2:39-43.
-
Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group. Cancer. 1991 May 01; 67(9):2235-40.
-
Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia. 1990 Feb; 4(2):95-9.
-
Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer. 1987 Jul 15; 60(2):149-55.